相关实验视频
Updated: May 7, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
9.6K
来自双重化学工程提取物的新半合成α-葡萄糖酶抑制剂
María I Osella1, Mario O Salazar1,2, Carlos M Solís2
1Consejo Nacional de Investigaciones Científicas y Técnicas, Suipacha 531, S2002LRK, Rosario, Argentina.
Natural products and bioprospecting
|January 4, 2025
概括
经过化学工程的 прополис提取物显著增强了α-葡萄糖酶抑制. 一种来自素的新型化皮拉,与其天然前体相比,显示了酶抑制的20倍增加.
科学领域:
- 药用化学 医学化学
- 自然产品化学 自然产品化学
- 酶抑制可以抑制酶.
背景情况:
- 化学工程提取物提供了新的半合成生物活性分子.
- 自然产品的衍生可以引入独特的元素和基层结构.
- 自然产品是药物发现和开发的丰富来源.
研究的目的:
- 为了研究化学工程天然提取物的α-葡萄糖酶抑制特性.
- 识别和描述来自自然来源的新生物活性化合物.
- 探索化学修饰对自然产品生物活性的影响.
主要方法:
- 通过与氨酸和化试剂的连续反应,制备14种化学工程提取物.
- 对准备的提取物α-葡萄糖酶抑制特性进行比较.
- 生物引导分化以分离出最强大的抑制剂.
- 隔离化合物的化学表征.
主要成果:
- 一种经过化学修饰的 прополис提取物显示出α-葡萄糖酶抑制的22倍增加.
- 从 прополис提取物中分离出一种新的化皮拉.
- 隔离的抑制剂来自于黄酸的化学转化.
- 与其天然前体相比,该抑制剂的α-葡萄糖酶抑制率大约增加了20倍.
结论:
- 自然提取物的化学工程是发现有力的生物活性分子的可行策略.
- 新型化皮拉是一种高效的α-葡萄糖酶抑制剂.
- 特定的化学转化,包括异环开放,脱氧化和化,增强生物活性.
相关概念视频
Glucagon-like Receptor Agonists
249
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
249
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
104
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
104
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Oral Hypoglycemic Agents: Glinides
108
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
108
Insulin: Biosynthesis, Chemistry, and Preparation
299
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
299

